Abstract
Metalloenzymes are widespread proteins, ubiquitous in all life kingdoms, being involved in various biosynthetic processes. Some of them have been extensively studied in mammals and there are excellent examples for mechanism- based inhibitor design. α-Carbonic anhydrases (CAs), matrix metalloproteinases (MMP), or angiotensin-converting enzyme (ACE), among others, are clinically exploited targets in the treatment or prevention of a variety of diseases such as congestive heart failure, hypertension, glaucoma, epilepsy, and cancer among others. The potential of metalloenzymes as anti-bacterial targets has been taken in consideration only recently. As approximately 3-5% of the bacterial genome encodes metalloenzymes, prokaryotic metalloenzymes such as Peptide Deformylase (PDF), α- β- and γ-CAs and Histidinol Dehydrogenase (HDH), have emerged as new promising antibacterial targets in the search of novel anti-infective agents that lack cross-resistance to existing drugs. Several of these enzymes are required for growth and virulence in several pathogenic species. Their inhibition therefore constitutes an important new approach which has been already successfully applied to the discovery of antibacterial agents active in vivo. This review illustrates and describes the progress which has been made in the design and the discovery of selective inhibitors of bacterial metalloenzymes as new antibacterial agents.
Keywords: Metalloenzymes inhibitors, antibacterial, peptide deformylase, carbonic anhydrase, histidinol dehydrogenase
Related Journals
Related eBooks
Related Articles
-
N-Valproyl-L-Phenylalanine as New Potential Antiepileptic Drug: Synthesis, Characterization and In Vitro Studies on Stability, Toxicity and Anticonvulsant Efficacy
Medicinal Chemistry Pathophysiology of Status Epilepticus Induced by Pilocarpine
Central Nervous System Agents in Medicinal Chemistry SLC1 Glutamate Transporters and Diseases: Psychiatric Diseases and Pathological Pain
Current Molecular Pharmacology The Role of T-Type Calcium Channels in Epilepsy and Pain
Current Pharmaceutical Design Effects of Brain IKKβ Gene Silencing by Small Interfering RNA on P-Glycoprotein Expression and Brain Damage in the Rat Kainic Acid-Induced Seizure Model
CNS & Neurological Disorders - Drug Targets Adeno-Associated Virus (AAV) Vectors in the CNS
Current Gene Therapy Histamine as an Anticonvulsant Inhibitory Neurotransmitter
Current Neuropharmacology Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology Neurochemical Imbalance in Epilepsy from Animal Model to Human
Current Psychopharmacology Timing is Everything
Current Neurovascular Research Past, Present and Future of Antiepileptic Drug Therapy - Finding a Place for Heterocyclics
Mini-Reviews in Medicinal Chemistry Chromosomal Micro-aberration in a Saudi Family with Juvenile Myoclonic Epilepsy
CNS & Neurological Disorders - Drug Targets Cell and Gene Therapies for Refractory Epilepsy
Current Neuropharmacology Pedunculopontine Nucleus Stimulation in Intractable Epilepsy: A Recent Patent on Deep Brain Stimulation Therapy
Recent Patents and Topics on Imaging (Discontinued) Molecular Biology of Nucleoside Transporters and their Distributions and Functions in the Brain
Current Topics in Medicinal Chemistry Altered Homeostatic Functions in Reactive Astrocytes and Their Potential as a Therapeutic Target After Brain Ischemic Injury
Current Pharmaceutical Design HCN Channel as Therapeutic Targets for Heart Failure and Pain
Current Topics in Medicinal Chemistry AMPA Receptor Antagonists: Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Recent Patents on Epilepsy Genetics
Recent Patents on DNA & Gene Sequences (DIscontinued) The Use of Antiepileptic Drugs in Paediatric Neurosurgical Conditions
Current Pharmaceutical Design